Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Zealand Pharma
  4. Zealand Pharma — Juni 2023

Zealand Pharma — Juni 2023

Planlagt Fastgjort Låst Flyttet Zealand Pharma
559 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #245

    God morgen 🙂

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #246

      En fantastisk nyhed 🙂

      1 Reply Last reply
      0
      • Y Offline
        Y Offline
        YPE
        wrote on sidst redigeret af
        #247

        Fantastisk:) Har markedet vidst det på forhånd eller kommer vi til at se en
        kursgevinst i næste uge? Det bliver spændende at se.

        1 Reply Last reply
        0
        • S Offline
          S Offline
          SMADK
          wrote on sidst redigeret af
          #248

          Godmorgen - super data. Meget spændende med fase III.

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Stroka
            wrote on sidst redigeret af
            #249

            God morgen. Det er vildt at vågne op til. 🙂

            1 Reply Last reply
            0
            • S Offline
              S Offline
              SMADK
              wrote on sidst redigeret af
              #250

              Jeg synes særligt kommentaren fra Carinne Brouillon er meget positiv. Boehringer er stærke og fremstår vældigt optimistiske.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                SMADK
                wrote on sidst redigeret af
                #251

                “With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver. We look forward to furthering our discussions with health authorities to advance this dual receptor ago

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  SMADK
                  wrote on sidst redigeret af
                  #252

                  dual receptor agonist into Phase III trials as we aim to help fill a treatment gap in this disease area.”

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    EliotSpitzer
                    wrote on sidst redigeret af
                    #253

                    Jeg glemt vist nok at sige god morgen tidligere men så tager vi lige den nu - God morgen på endnu en flot solskins dag!

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #254

                      Zealand Pharma: Data shows nearly 19% weight loss https://www.proinvestor.com/boards/113406

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        EliotSpitzer
                        wrote on sidst redigeret af
                        #255

                        SMADK - Det var aboslut interessante citater fra Carinne Brouillon.

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          SMADK
                          wrote on sidst redigeret af
                          #256

                          Rygterne kom midt på ugen, men uden officielle meldinger. Sommetider er gode rygter nok til en stigning i kursen, men det skete kun kortvarigt her.
                          Mon ikke udmeldingen af disse data afføder en stigning på mandag. Det vil være min forventning.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            EliotSpitzer
                            wrote on sidst redigeret af
                            #257

                            AstraZeneca har droppe udviklingen af AZD0186, som var en oral GLP-1. Det er anden GLP-1 kandidat, som AZ har droppe og de lukker nu GLP-1 programmet ned. https://www.fiercebiotech.com/biotech/astrazeneca-drops-another-glp-1-after-phase-1-data-busts-market-beating-diabetes-hopes

                            1 Reply Last reply
                            0
                            • H Offline
                              H Offline
                              HanneP
                              wrote on sidst redigeret af
                              #258

                              Godmorgen til længe ventede stærke nyheder. Tak for info til alle. 🙂

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                EliotSpitzer
                                wrote on sidst redigeret af
                                #259

                                Her er en artikel, hvor læge og Boehringer Ingelheim’s corporate vice president og chef for cardiometabolisk medicin, Waheed Jamal, udtaler sig om den læringskurve som BI har været igennem i tolkningen af studiet. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients

                                1 Reply Last reply
                                0
                                • Y Offline
                                  Y Offline
                                  YPE
                                  wrote on sidst redigeret af
                                  #260

                                  Tak, Eliot. God artikel

                                  1 Reply Last reply
                                  0
                                  • Y Offline
                                    Y Offline
                                    YPE
                                    wrote on sidst redigeret af
                                    #261

                                    Gad godt vide, om der er tyske store investorer, som er investeret i/holder øje med Zealand. Boehringer er jo en kæmpe virksomhed, men de er ikke børsnoteret. Deres indgangsvinkel til fedmemarkedet kunne jo være Zealand Pharma.

                                    1 Reply Last reply
                                    0
                                    • A Offline
                                      A Offline
                                      Aps_invest
                                      wrote on sidst redigeret af
                                      #262

                                      “What we'll take forward into the phase 3 is that we will have a much lower titration—probably somewhere around every four weeks as opposed to every two weeks that we've had in phase 2,” he said. “We will allow plenty of flexible titration throughout the trial in phase 3.”

                                      Boehringer is now in discussions with regulators about launching a phase 3 trial, Jamal said, though he didn’t reveal an anticipated timeline. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #263

                                        Tak ApS invest. Dette link duer. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #264

                                          Lægger alle de relevant links ind her de kommende dage: https://www.proinvestor.com/boards/113406/

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper